HAVCR1 and in situ carcinoma: All Veh/CIS treated mice exhibited tubular injury after just two doses of cisplatin as measured by urinary KIM-1 and had significantly higher pathological tubular injury scores than Veh/Veh and BARD/Veh mice (p < 0.05; Fig. S1A).